Skip to content

    Supriya Lifesci.

    SUPRIYAGood
    Healthcare·14 Aug 2025
    Management Summary

    Supriya Lifescience reported a challenging Q1 FY26 with a 10% YoY revenue decline to ₹145 crores and a 17% YoY EBITDA degrowth to ₹52 crores. This was primarily attributed to production delays caused by repair and maintenance work at the Lote facility. Despite the short-term setback, the company maintained strong EBITDA margins at 36% and saw improved backward integration to 81%. Management expressed confidence in recovering lost sales in H2 FY26 and reiterated its FY27 revenue target of ₹1,000 crores, driven by new product launches and CDMO opportunities.

    Highlights

    8
    • Revenue for Q1 FY26 stood at ₹145 crores, reflecting a 10% year-on-year decline from ₹161 crores in Q1 FY25.

    • EBITDA for Q1 FY26 was ₹52 crores, a 17% year-on-year degrowth from ₹63 crores in Q1 FY25, with EBITDA margins at 36%.

    • PAT for Q1 FY26 was ₹35 crores, down from ₹45 crores in Q1 FY25, with PAT margin at 24%.

    • Exports remained the mainstay of the business, contributing 85% of Q1 FY26 revenue, with European market share increasing to 41% from 36% in Q1 FY25.

    • Backward integration improved significantly to 81% in Q1 FY26 from 69% in Q1 FY25.

    • Q1 FY26 CAPEX stood at ₹14 crores, with an additional ₹65 crores expected for the remaining FY26.

    • The company aims to achieve ₹1,000 crores in revenue by FY27, supported by 3-4 product launches planned for FY26.

    • Commercial contributions from the Ambernath site (liquid anesthetics and oral solids) are expected from Q4 FY26.

    Concerns

    1
    • Production Delays due to Maintenance

    What Changed1

    vs Q2 FY26

    Risks discussed3 → 4 (+1)

    Key financials

    Single quarter

    06 metrics
    1. 01Revenue₹145 Cr-10%YoY
    2. 02EBITDA₹52 Cr-17%YoY
    3. 03EBITDA Margin36%
    4. 04PAT₹35 Cr
    5. 05PAT Margin24%

    Guidance & targets

    18
    CategoryTargetPriority
    Revenue
    Annual Revenue Growth
    ~20%
    High
    Revenue
    Total Revenue
    ₹1,000 crores
    High
    Profitability
    EBITDA Margin
    33% to 35%
    High
    Product Launches
    New Product Launches
    3 to 4
    High
    Capex
    Remaining CAPEX
    around ₹65 crores
    High
    CDMO
    Ambernath Commercial Contributions
    Q4
    Medium
    CDMO - Whey Protein
    Contract Signing
    end of quarter 2
    High
    CDMO - Whey Protein
    Revenue Generation
    small revenue
    Medium
    CDMO - Whey Protein
    Revenue Potential
    ₹40 crores, ₹50 crore
    Medium
    CDMO - Whey Protein
    Revenue Potential (Long-term)
    ₹100 crores
    Low
    CDMO - Whey Protein
    Volume
    about 50 tonnes
    Medium
    CDMO - DSM Contract
    Revenue
    ₹30-35 crores
    High
    Product Launch
    Contrast Media Launch
    Q2
    High
    Product Launch
    ADHD Product Launch
    Q4
    High
    Market Share
    Contrast Media Market Share
    20-25%
    High
    Regulatory Filings
    US DMF Filings
    much higher
    High
    New Facilities
    Patalganga Possession
    within next 15, 20 days
    High
    Growth Split
    Volume vs Value Growth
    50%-50%
    Medium

    Risks & concerns

    6
    RiskSeverity

    Production Delays due to Maintenance

    Q1 FY26 revenue decline was primarily due to delays in production facility campaigns and maintenance work at the Lote facility's older blocks (A, B, C) needed to support Module E.Management acknowledged

    high

    US Tariff Uncertainty

    Uncertainty around US tariff measures, though the US market is a small share of current revenue, management is tracking developments but has not fully assessed the impact.Both acknowledged

    medium

    Cyclical Nature of CDMO/API Business

    Analyst raised concern about historical cyclicality in CDMO/API. Management believes their robust portfolio, niche product selection, backward integration, and regulatory approvals mitigate this risk.Analyst downplayed

    low

    New Product Scale-up Time

    Scaling up new products in regulated markets takes 2-3 years from launch, impacting immediate revenue contribution from new launches.Management acknowledged

    low

    Areas of Evasion(2)

    • Detailed assessment of US tariff impact
    • Specific breakdown of backward integrated products into regulated/semi-regulated markets

    Q&A highlights

    3

    “So, the revenue drop was primarily due to the delay in the production facility campaign, which happened because of the repair and maintenance work that we had taken up at the Lote site. As you know, we have recently started commercial production in our Module E, which is one of our biggest production blocks with a capacity of 350 KL.”

    Clarified the primary reason for the revenue miss, attributing it to internal maintenance rather than demand issues, and explained the interdependency of production modules.

    asked by Adityapal from MSA Capital Partners

    2 min read6 chapters

    Detailed Narrative

    01

    Q1 FY26 Performance Overview and Revenue Decline Drivers

    Supriya Lifescience reported Q1 FY26 revenue of ₹145 crores, marking a 10% year-on-year decline from ₹161 crores in Q1 FY25. EBITDA also saw a 17% degrowth to ₹52 crores, though EBITDA margins remained strong at 36%. The primary reason for this decline was attributed to delays in the production facility campaign, specifically repair and maintenance work undertaken at the older Lote facility blocks (A, B, C) to support the newly operational Module E. Management expects to recover these lost sales in the second half of FY26.

    02

    Strategic Focus: Backward Integration and Market Expansion

    The company's backward integration efforts continued to yield results, with the percentage rising to 81% in Q1 FY26 from 69% in Q1 FY25, strengthening control over key inputs and reducing external dependence. Exports contributed 85% of Q1 FY26 revenue, with the European market share increasing to 41% from 36% in Q1 FY25. This strategic focus on regulated markets and backward integration is expected to sustain EBITDA margins in the 33-35% range.

    03

    CDMO and New Product Pipeline Update

    Supriya Lifescience is actively pursuing its CDMO strategy, with the Ambernath site commencing validation campaigns for liquid anesthetics and oral solids, expecting commercial contributions from Q4 FY26. The company plans 3-4 new product launches in FY26 across therapeutic areas like anesthetics, antidiabetics, and ADHD. The anesthetic molecule has a market size of $300 million, ADHD $90 million, and cardiovascular intermediate $100 million, indicating a focus on larger global opportunities.

    04

    Whey Protein and DSM Contract Progress

    The Whey Protein contract is in its final stage, expected to be signed by the end of Q2 FY26, with small revenue generation anticipated from Q4 FY26. The long-term potential for this product is significant, aiming for ₹40-50 crores in 3-4 years and scaling up to ₹100 crores in 4-5 years. However, the FY26 volume guidance for Whey Protein was revised downwards to about 50 tonnes from the earlier 100 metric tons. The DSM contract is on track to contribute ₹30-35 crores in revenue for the full FY26, with CEP approval already received for Europe.

    05

    Contrast Media and Regulatory Filings

    The contrast media product is scheduled for launch in Q2 FY26. Management is confident in gaining a 20-25% market share for this product within 3-4 years, leveraging cost and technology advantages, along with full backward integration. The company also plans to significantly increase its US DMF filings in the next 3-4 years for new products, indicating a stronger focus on the US regulated market going forward.

    06

    Patalganga Expansion and Future Capacity

    The environmental clearance for the Patalganga site has been received, and the company expects to take possession within 15-20 days, with construction activity to commence thereafter. This new site, planned for API and finished formulation, will support the next leg of expansion and ensure sufficient manufacturing capacity to handle growth beyond the guided 20% annual rate, especially for larger molecules being targeted.

    This is an AI-generated summary of a publicly available earnings call transcript. It is for informational purposes only and does not constitute investment advice, a recommendation, or an endorsement. inve.money is not a SEBI-registered investment advisor. Please consult a qualified financial advisor before making any investment decisions.